Delee has created the CytoCatch, a blood-testing device for the early diagnosis of cancer.
This device isolates what are called circulating tumor cells, or “CTCs,” from the blood. According to Grand View Research, by 2027, the global market for analyzing CTCs is projected to surpass $18 billion.
Unlike other devices, CytoCatch possesses the required sensitivity and specificity needed to analyze the CTC’s genetic features and biomarkers. This facilitates the early detection of cancer and enables physicians to create personalized treatments.
Delee’s notable investors include Y Combinator and StartX. The company has built a commercial version of its device, and aims to begin sales by Q4 2022.